Allogene Therapeutics, Inc.
1.2200-0.04 (-3.17%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · ALLO · USD
Key Stats
Market Cap
270.69MP/E (TTM)
-Basic EPS (TTM)
-1.10Dividend Yield
0%Recent Filings
8-K
IP lawsuit hits TALEN tech
Allogene Therapeutics faces potential IP risks after Factor Bioscience sued its licensor Cellectis on September 26, 2025, for infringing TALEN gene-editing patents, technology Allogene relies on for CAR T candidates like cema-cel and ALLO-316. Though not a defendant, Allogene could face direct claims as a user. Cellectis disputes the allegations and plans a strong defense. Litigation threatens pipeline progress.
8-K
Allogene Q2 results and updates
Allogene Therapeutics reported Q2 2025 financials, posting a $50.9 million net loss amid $40.2 million R&D spend, while ending with $302.6 million in cash to fund operations into 2H 2027. Key advances include the ALPHA3 trial's pivot to a randomized design using standard FC lymphodepletion for cema-cel in LBCL, with over 50 sites activated and futility analysis set for 1H 2026. ALLO-329's RESOLUTION trial launched in rheumatology, targeting autoimmune diseases without full lymphodepletion; ALLO-316 aligned with FDA on pivotal RCC design post-ASCO data. Progress sharpens focus on scalable CAR T therapies, yet clinical risks persist.
10-Q
Q2 FY2025 results
Allogene Therapeutics narrowed its Q2 FY2025 net loss to $50.9M from $66.4M y/y, driven by 20% lower operating expenses as R&D costs fell 20% to $40.2M amid manufacturing cuts and a 28% workforce reduction, while G&A dipped 11% to $14.3M. Cash burn eased, with $302.6M in cash and investments at quarter-end supporting operations into H2 2027 after $11.5M from ATM offerings. Key drivers included $6.9M cema-cel spend and $2.4M impairment on subleased assets, offset by $6.2M interest income. Liquidity remains solid with no debt, but clinical risks loom from ALPHA3's MRD screening challenges.
8-K
Allogene drops ALLO-647 in trial
Allogene Therapeutics selected standard fludarabine and cyclophosphamide as the lymphodepletion regimen for its ALPHA3 study of cema-cel in first-line LBCL consolidation, closing the ALLO-647 arm after a fatal hepatic failure from adenovirus infection tied to immunosuppression. No adenoviral cases appear in FC-only treatments across trials. The trial now randomizes cema-cel plus FC against observation. Risks persist from novel tech side effects. Futility analysis hits in H1 2026.
8-K
Annual meeting results
Allogene Therapeutics held its 2025 Annual Meeting on June 18, electing Elizabeth Barrett, Arie Belldegrun, and David Chang as Class I directors until 2028, with strong support for Belldegrun and Chang despite some withheld votes for Barrett. Stockholders approved executive compensation on an advisory basis and ratified Ernst & Young as auditors for 2025. Directors secured. No major dissent disrupts governance.
ACET
Adicet Bio, Inc.
0.75-0.11
ALLR
Allarity Therapeutics, Inc.
1.42-0.04
APVO
Aptevo Therapeutics Inc.
1.42-0.04
ARTV
Artiva Biotherapeutics, Inc.
4.39-0.34
AUTL
Autolus Therapeutics plc
1.46-0.08
CERO
CERo Therapeutics Holdings, Inc
1.79-0.09
CGEM
Cullinan Therapeutics, Inc.
7.69-0.80
CLLS
Cellectis S.A.
3.63+0.05
CRBU
Caribou Biosciences, Inc.
2.37-0.10
LYEL
Lyell Immunopharma, Inc.
16.59-0.12